Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.
Emily K Sims, Rachel E J Besser, Colin Dayan...
https://pubmed.ncbi.nlm.nih.gov/35316839/Actively Recruiting
Led by Sanford Health · Updated on 2026-03-02
33000
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are studying the feasibility of screening the general population of children for type 1 diabetes T1D and celiac disease autoantibodies during routine healthcare visits. The study aims to identify children at risk for T1D early to prevent serious illness at diagnosis and improve long-term health outcomes. This observational study is conducted within an integrated health system in partnership with the Helmsley Charitable Trust. Children are screened for blood markers related to T1D and celiac disease at specific ages newborns at birth, then at 1, 2, and 5 years old, or once between 9 and 16 years old. Siblings of children with T1D autoantibodies, aged 6 to 17 years, also undergo one-time screening. The study includes serum and whole blood sampling for genetic risk scores and autoantibodies, with optional gene expression testing from cord blood and peripheral blood. Participants will receive routine care at Sanford facilities, and the study involves blood tests collected at scheduled ages. Researchers will monitor the occurrence of autoantibodies, track seroconversion rates, and record referrals to clinical care for celiac disease. The primary outcome is demonstrating the feasibility of large-scale population screening by year 10. Participants may be offered enrollment in additional monitoring or prevention studies if autoantibodies are detected, and safety and cost assessments will be conducted during the study period, which continues until 2031.
CONDITIONS
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
A
Ann Mays, RN, CPN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sanford Health
Lead Sponsor
The Leona M. and Harry B. Helmsley Charitable Trust
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) during routine healthcare delivery
Duration - Up to 16 years depending on age group
Participants undergo blood sampling for genetic risk scoring and autoantibody testing at specific ages during routine care.
Blood sampling at birth, 1 year, 2 years, 5 years, once between 9 and 16 years, or one-time for siblings aged 6 to 17 years
Duration - Up to 10 years
Participants with confirmed autoantibodies are monitored for type 1 diabetes risk and referred to further monitoring or clinical care.
Ongoing observation through routine healthcare visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Emily K Sims, Rachel E J Besser, Colin Dayan...
https://pubmed.ncbi.nlm.nih.gov/35316839/Sanford Health
Lead Sponsor
The Leona M. and Harry B. Helmsley Charitable Trust
Collaborating Sponsor